Company: BFRG
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023496
Chunk: 71

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 8
Chunk 71
---
 clinical development programs. We believe the bfLEAP™ platform is ideally suited for
evaluating pre-clinical and clinical trial data generated in translational research and clinical trial settings in order to lead to faster,
less expensive drug approvals.

Our
aim is to improve the odds of success in each stage of developing medicine, ranging from early pre-clinical through late-stage clinical
development. Our ultimate objective is to utilize bfLEAP™ to enable the success of ongoing third-party clinical trials or rescue
late-stage failed drugs (i.e., Phase II or Phase III clinical trial failures) for in-house development and divestiture. We will also
consider collaborations for earlier stage drugs.

We
intend to continue to evolve and improve bfLEAP™, either in-house or with development partners like JHU-APL. We plan to leverage
our proprietary AI/ML platform developed over several years at one of the top innovation institutions in the world, which has already
been successfully applied in multiple sectors.

We
operate and have staffed our business using funds from our initial public offering and subsequent financings, have entered into partnerships
and relationships, completed our first commercial service contract with a leading rare disease non-profit organization for AI/ML analysis
of late-stage clinical data in 2023, and completed our collaboration agreement for clinical trial optimization with a Phase III oncology
company focused on novel chemotherapeutic treatments for rare cancers in the third quarter of 2025. We have also acquired the rights
to a series of preclinical and early clinical drug assets from universities, as well as entered into a strategic collaboration with a
world-renowned research institution to create a HSV1 viral therapeutic platform to engineer immunotherapies for a variety of diseases.
We have signed exclusive worldwide license agreements with Johns Hopkins University (“JHU”) for a cancer drug that targets
glioblastoma (brain cancer), pancreatic cancer, and others. We have also signed an exclusive worldwide license from George Washington
University for another cancer drug that targets hepatocellular carcinoma (liver cancer) and other liver diseases. In addition, we signed
three-year strategic data and commercialization agreements with the Lieber Institute for Brain Development (“LIBD”) whom
we believe has a repository of the largest collection of postmortem brains in the world, including molecular, clinical, and other data.
The objective of this collaboration with LIBD is for the Company to analyze these rich data sets using its proprietary AI/ML tools and
models and then go